(redirected from Desirudin)
Also found in: Medical.
Related to Desirudin: Lepirudin


 (hîr-o͞od′n, hîr′ə-dən, -yə-)
A substance secreted by the buccal glands of leeches, capable of preventing coagulation by inactivating thrombin and used in medicine as an anticoagulant.

[Originally a trademark, from Latin hirūdō, leech.]


(Pharmacology) med an anticoagulant extracted from the mouth glands of leeches
[C20: from Latin hirudin-, hirudo leech + -in]


(ˈhɪr yə dɪn, ˈhɪr ə-, hɪˈrud n)

a polypeptide obtained from the buccal gland of leeches, used in medicine chiefly as an anticoagulant.
[1900–05; formerly trademark]
References in periodicals archive ?
The Pediatric Health Information System database was queried for pediatric patients discharged from January 1, 2004 to December 31, 2011 if they received one of the following DUs during admission: argatroban, bivalirudin, desirudin, or lepirudin.
The study was a randomised, open-label, exploratory study comparing fixed-dose, SC desirudin vs.
The study compared desirudin with argatroban, the current standard of care.
Study Findings of Desirudin for DVT Prophylaxis Published in Clinical and Applied Thrombosis and Hemostasis
DESIR-ABLE, a multicenter, open-label, single-arm study of desirudin (Revasc[R], Iprivask[R]) demonstrated the clinical utility and safety profile of desirudin for prevention of dangerous blood clots in a broad population of surgical and medically ill patients.
Blood clots and post-operative bleeding were reduced with use of desirudin, a new type of anticoagulant.
Results of the study, entitled "Impact Of Stage 3B Chronic Kidney Disease On Thrombosis And Bleeding Outcomes After Orthopedic Surgery In Patients Treated With Desirudin Or Enoxaparin: Insights From A Randomized Trial," were published online ahead of print on June 4, 2012.
Canyon holds exclusive world-wide rights to desirudin, a subcutaneous (SC) recombinant direct thrombin inhibitor (DTI), and to pegmusirudin, a pegylated recombinant DTI with a longer duration of action than desirudin.
Desirudin reduced major venous thromboembolism (VTE) and post-operative bleeding compared with the standard of care, enoxaparin, in patients with poor kidney function undergoing orthopedic surgery, according to a poster presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) meeting.
It was based on a retrospective analysis of the large, randomized trial that served as the pivotal trial in the approval by the Food and Drug Administration of desirudin.
PREVENT-HIT Study Finds Desirudin Merits Further Study; Findings Presented At Hemophilia & Thrombosis Research Society Scientific Symposium
Desirudin becoming available is a step forward in that direction," said Craig Kessler, MD, Georgetown University Professor of Medicine and Pathology and Section Chief of Hematology.